Physician profile
Cherry Chen
NPI 1730445727
$2,712.31
in general payments reported to CMS, 2019-2025
20 companies · $1,241 in 2025
The $1,241 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $92.99 · 2022: $22.10 · 2023: $19.00 · 2024: $127 · 2025: $1,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $884.92 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $427.68 | 2019-2024 | Xarelto |
| Pfizer INC. | $250.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $142.92 | 2019-2023 | Lokelma |
| Vifor Pharma, INC. | $135.85 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.81 | 2019-2025 | Xifaxan |
| Cumberland Pharmaceuticals, INC. | $112.39 | 2019-2020 | |
| Csl Behring | $88.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $80.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $74.49 | 2025 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.51 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $67.39 | 2019 | |
| Astellas Pharma US INC | $56.19 | 2019 | |
| Aimmune Therapeutics, INC. | $51.15 | 2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $49.49 | 2019-2025 | Eliquis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $28.64 | 2025 | Ultomiris |
| Eusa Pharma (US) LLC | $19.16 | 2019 | |
| Melinta Therapeutics, LLC | $17.53 | 2024 | Kimyrsa, Rezzayo |
| Paratek Pharmaceuticals, INC. | $17.26 | 2020 | |
| Mylan Specialty L.P. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.